Pfizer's experimental, long-acting opioid painkiller can be subjected to manipulation and abuse. The U.S. Food and Drug Administration's advisory committees will discuss on June 8 whether the drug should be approved.
Pfizer's experimental, long-acting opioid painkiller can be subjected to manipulation and abuse. The U.S. Food and Drug Administration's advisory committees will discuss on June 8 whether the drug should be approved.